Stronger hearts, smarter care: how telemedicine is transforming heart failure outcomes

This invited commentary refers to ‘Effectiveness of a nurse-led telemedicine-based program for pharmacological and prognostic optimization of patients with heart failure and reduced ejection fraction: the MAR-HF-Titration study’ by S. Ruiz-Bustillo et al., https://doi.org/10.1093/eurjcn/zvaf161. Heart failure remains a major cause of morbidity, mortality, and healthcare utilization worldwide. Despite advances in pharmacological and device based therapy, outcomes remain sub optimal for many patients. Central to improving prognosis is the timely initiation and titration of evidence-based therapies to guideline recommended doses that are associated with better survival and reduced hospitalizations. In practice, achieving this goal is often slow, fragmented, and resource intensive as healthcare systems and local pathways are not currently designed to support this. Over the past two decades, landmark trials have established the benefit of four core therapeutic classes for patients with heart failure with reduced ejection fraction: angiotensin-converting enzyme inhibitors or angiotensin receptor–neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium glucose cotransporter 2 inhibitors. International guidelines recommend initiating and titrating all four to maximum tolerated doses as rapidly as clinically feasible. In this issue, a nurse-led telemedicine service is emerging as a powerful tool to accelerate optimization, improve accessibility to healthcare, and offer a patient centric model of healthcare delivery.1 The service utilizes specialist knowledge and provides continuity of care provided by heart failure nurses with the flexibility of a virtual platform. Results demonstrate that proactive monitoring and timely treatment adjustments undertaken via a remote platform leads to a reduction in N-terminal pro b-type natriuretic peptide levels, decreased diuretic requirements, and more efficient medication optimization. However, translating this into practice is challenging. Traditional care pathways often require multiple in-person visits, separated by weeks to assess tolerance and adjust medicine doses. Barriers to optimization include capacity issues, the need to travel to specialist centres, limited availability of heart failure clinics, and the competing demands on both patient and healthcare systems. In rural and underserved regions, access to specialist titration services may be particularly limited, resulting in long waits and delayed therapy escalation. Emerging trials such as STRONG-HF have shown that rapid up titration of therapy with close follow-up can lead to improved outcomes. However, the trial environment provided intensive contact and monitoring not easily replicated in routine care. The question has remained: how do we operationalize these benefits in busy, resource-limited systems? A structured nurse-led telemedicine programme offers a practical solution. Patients are reviewed remotely at predetermined intervals, often weekly or bi-weekly, using secure video or telephone consultations. Blood pressure, weight, heart rate, and symptoms are collated regularly and submitted electronically or relayed verbally, thus enabling the team to make informed recommendations in real time. Protocol-driven titration can be implemented swiftly with consultation from a supervising cardiologist as required. This model reduces travel burden for patients, allows more frequent touchpoints without overloading physical clinics, and maintains a strong therapeutic relationship between nurse and patient. For the healthcare system, it frees up in-person capacity for those requiring physical examination, advanced imaging, or urgent assessment. Not all patients are candidates for telemedicine. Factors such as language barriers, digital literacy, cognitive impairment, or inability to perform home measurements may limit suitability. In such cases, in-person follow-up remains essential. Additionally, telemedicine must be supported by robust training, clear protocols, and integration with electronic health records to ensure safety and continuity of care. By empowering heart failure nurses with digital tools and structured protocols, we can transform the speed and quality of heart failure optimization. The evidence is growing and suggests rapid titration is not simply about convenience, it is about delivering better, faster, and patient-centric care. Paul Wright (Conceptualization [lead], Writing—original draft [lead]) Received honorarium for delivering eductional sessions on behalf of Astra Zeneca, no influence nor input into the content of the editorial. This commentary does not contain new data.